 Intra-Cellular Therapies Inc NASDAQ: ITCI expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in collaboration with Catalent Inc NYSE: CTLT, using its proprietary Zydis ODT orally disintegrating tablet fast-dissolving formulation. 